Interferon-β/glatiramer acetate treatment during lactation in women with multiple sclerosis
Author(s): ,
A.I. Ciplea
Affiliations:
Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum; Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
,
A. Stahl
Affiliations:
Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum
,
S. Thiel
Affiliations:
Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum
,
R. Gold
Affiliations:
Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum
K. Hellwig
Affiliations:
Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum
ECTRIMS Online Library. Hellwig K. Oct 12, 2018; 228846; P1004
Kerstin Hellwig
Kerstin Hellwig
Contributions
×
Abstract

Abstract: P1004

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Epidemiology

Introduction: Interferon-β (IFN-β) and glatiramer acetate (GLAT) are large molecules which are unlikely to enter the breastmilk. However, their effect during breastfeeding on child development or relapse risk is still unknown.
Objective: To assess child development of breastfed children and relapse risk of mothers breastfeeding under IFN-β or GLAT.
Methods: We present data on 76 pregnancies in 72 women, who were prospectively enrolled in the German MS and Pregnancy Registry between 2011 and 2017 and followed up 1.5 years±0.8 (mean±SD) postpartum. Data on disease activity and child development was obtained with a standardized questionnaire.
Results: 41 women received IFN-β and 35 GLAT. Most of the women (47 (61.8%)) restarted treatment 32 days (0-483) after delivery. 13 (27.7%) had at least one relapse with a median of 83 (32-704) days after birth; 8 (61.5%) restarted treatment during breastfeeding due to a relapse. Of 18 (23.7%) women who maintained therapy during the entire pregnancy only 1 (5.6%) relapsed during lactation. In the remaining 11 cases (14.5%) treatment was (re-)started during pregnancy (median 210 days after last menstrual period (109-260)), one after a relapse; here 2 women (18.2%) relapsed during lactation. At 12 and 24 months children's body length and weight were within the normal range of 3rd to 97th percentile (median: 75.50 and 9435.00 and 87.25 and 11600 respectively). Most reported adverse events were developmental delays regarding motor skills (4%), in line with the 5-6% prevalence in general population. Follow up of child development and enrollment of new patients are ongoing; the results will be reported at the meeting.
Conclusions: IFN-β/GLAT treatment during lactation doesn't seem to negatively influence important characteristics of child development like body length, weight or reaching development milestones. The effect on postpartum disease activity has still to be determined..
Disclosure: A. I. Ciplea: Has nothing to disclose
A. Stahl Has nothing to disclose
S. Thiel: Has nothing to disclose
R. Gold: Has served on the scientific advisory board for Teva Laquinimod DSMB, received speaker honoraria from Biogen, Genzyme, Teva, Merck Serono, Bayer Schering, Ozgene, Novartis, is on the Editorial board for SAGE Journal, Aktuelle Neurologie, Experimental Neurology.
K. Hellwig: Has received travel grants from Biogen, Novartis and Merck; received research honoraria from Bayer Healthcare, Biogen Idec Germany, Merck Serono, Teva Pharma, Novartis Pharma, Sanofi Genzyme; speaker honoraria from Bayer Healthcare, Biogen Idec Germany, Merck Serono, Teva Pharma, Novartis Pharma,Sanofi Genzyme, Roche and worked as a consultant for Teva Pharma, Sanofi Genzyme, Merck and Roche.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies